Oxford Ledge
Search
No licensed closing price on file for ELDN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 12:40 UTC.
Eledon is a clinical stage biotechnology company developing tegoprubart, an antibody that blocks the CD40L pathway to prevent organ rejection after transplantation and treat amyotrophic lateral sclerosis. The company's lead compound is engineered to modify immune cell activation without depleting lymphocytes, potentially offering safety advantages over earlier anti-CD40L approaches. Eledon prioritizes kidney transplantation programs, as kidney transplants are the most common solid organ transplant in the U.S., though there remains a critical shortage of available kidneys.
Summarized from Eledon Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | 209.29% |
Eledon is a clinical stage biotechnology company developing tegoprubart, an antibody that blocks the CD40L pathway to prevent organ rejection after transplantation and treat amyotrophic lateral sclerosis.
Eledon Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 12:40 UTC. This page is also available as JSON at /api/data?ticker=ELDN and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ELDN and 5,000+ tickers.
Create a free account — keep ELDNGET /api/data?ticker=ELDN
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt